What is the prevalence of Hypereosinophilic Syndrome?

Hypereosinophilic syndrome (HES) is an ultra-rare group of blood disorders characterized by persistent overproduction of eosinophils, with an estimated prevalence of approximately 0.36 to 6.3 cases per 100,000 people. Because HES is frequently underdiagnosed or misdiagnosed as other inflammatory conditions, these figures are considered conservative estimates rather than exact counts.

What is the estimated prevalence and incidence of Hypereosinophilic syndrome?

Due to the complexity of diagnosing Hypereosinophilic syndrome, precise global data remains elusive. Current literature, including data from Orphanet, suggests that Hypereosinophilic syndrome is considered rare, often presenting as a spectrum of disorders rather than a single entity. Incidence rates are difficult to calculate accurately, though some studies suggest an annual incidence of roughly 0.036 cases per 100,000 individuals. Within the DiseaseMaps.org community, three individuals have identified as living with this condition, highlighting the rarity and the value of patient-led registries in understanding the real-world impact of Hypereosinophilic syndrome.

Who is most affected by Hypereosinophilic syndrome?

While Hypereosinophilic syndrome can affect individuals of any age, onset typically occurs between the ages of 20 and 50. Clinical observations indicate some variations in how the disease manifests across populations:

• Gender distribution: While idiopathic forms of Hypereosinophilic syndrome may affect both genders equally, certain subtypes, such as lymphocytic-variant HES, may show a slight female predominance.


• Age of onset: Although most common in adults, pediatric cases of Hypereosinophilic syndrome are well-documented and require specialized pediatric hematology care.


• Geographic factors: There is no clear evidence of ethnic or geographic clustering; however, high rates of parasitic infections in certain regions can mimic the eosinophilia seen in Hypereosinophilic syndrome, complicating diagnostic accuracy.

Why is accurate data on Hypereosinophilic syndrome challenging to collect?

The primary challenge in mapping Hypereosinophilic syndrome is the diagnostic threshold. Because eosinophilia is a common response to allergies, parasites, and medications, patients are often managed for these secondary causes before a diagnosis of Hypereosinophilic syndrome is considered. Furthermore, the molecular heterogeneity of the disease—ranging from FIP1L1-PDGFRA mutations to idiopathic forms—means that many patients may remain undiagnosed or misclassified in medical records, leading to a significant gap between clinical prevalence and estimated prevalence.

Next steps

• Consult a hematologist or an immunologist specializing in eosinophilic disorders.


• Consider genetic testing to determine if your specific type of Hypereosinophilic syndrome has a targetable mutation.


• Join the DiseaseMaps.org community to connect with other patients and share your journey.


• Maintain a detailed log of your symptom flares and eosinophil counts to assist your clinical team.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• Orphanet: Hypereosinophilic syndrome (ORPHA:408)


• NIH Genetic and Rare Diseases Information Center (GARD): Hypereosinophilic syndrome


• OMIM (Online Mendelian Inheritance in Man): Entry #607685


• American Partnership for Eosinophilic Disorders (APFED)